Drug Profile
Research programme: nanotechnology-based therapeutics - Ferring Pharmaceuticals
Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Ferring Pharmaceuticals
- Developer Ache Laboratories; Ferring Pharmaceuticals
- Class Peptides; Proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastrointestinal disorders
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for research development in Gastrointestinal-disorders in Brazil (PO)
- 30 Nov 2016 Early research in Gastrointestinal disorders in Brazil (PO)
- 30 Nov 2016 Ferring Pharmaceuticals and Ache Laboratories enter into collaboration to develop nanotechnology-based therapeutics